Download Databook
Download Sample
Table of Content
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
May 2025
The global next-gen COVID-19 vaccine market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2025 to 2034. This surge is attributed to evolving consumer preferences and technological advancements reshaping the industry.
The next-gen COVID-19 vaccine market is estimated to grow significantly due to the growing number of COVID-19 cases. Apart from this, the viruses mutate rapidly then other organisms, due to which the development of new vaccines becomes necessary to ensure that people build immunity against the new variants. Additionally, many government initiatives are being taken in different countries to tackle the ongoing issues of COVID-19 and to prevent the occurrence of any pandemic in the future. Many companies are collaborating with each other and government organizations to conduct clinical trials for developing next-gen COVID-19 vaccines.
Companies are still researching vaccinations with novel concepts and ideas, even after the COVID-19 outbreak ended about two years ago. This is due to the fact that COVID-19 instances are still occurring and that prevention and therapy must change along with the virus itself. The COVID-19 pandemic's medical, social, and economic costs, as well as the development and appearance of new strains, have brought attention to the pressing need for next-generation vaccines that are more durable, have a wider range of protection, and can stop infection and transmission.
With the advent of artificial intelligence (AI), a new era in vaccine development has dawned, offering unprecedented opportunities to accelerate the process. Machine learning and deep learning are examples of artificial intelligence (AI) systems that use genetic information, immune system connections, and protein structures to predict antigenic epitopes, assess immunogenicity, and rank antigens for more research. These cutting-edge technologies provide opportunities never before possible. As AI-driven vaccine research advances and computer resources become more accessible, it holds great promise to transform public health and combat infectious diseases worldwide.
Genetic Mutation in the Virus Promotes the Need for New Vaccines
Rapid viral evolution has led to several instances throughout human history where newly emerging viruses have posed a serious threat to public health. It was expected that SARS-CoV-2 variants would evolve given the large global prevalence of COVID-19 infections. Even while vaccinations have been the most effective tool in the fight against the pandemic, there are still a number of obstacles to overcome. The introduction of viral variations is one of the most immediate risks.
High Cost of Vaccine Development
The high cost of vaccine development hampers the next-gen COVID-19 vaccine market. The direct expenses of producing a vaccine include the price of labor, raw materials, components, analytics, and the documentation of the procedure and test findings. The development and administration of quality systems, production and QC planning, distribution and warehousing, inventory control, and overhead activities like marketing, sales, and regulation are examples of indirect expenses.
Is mRNA the Future of the Next-Gen COVID-19 Vaccine Market?
mRNA vaccines' enormous therapeutic potential has been highlighted by the COVID-19 pandemic. Twenty-three (17%) of the COVID-19 vaccines now undergoing clinical trials are mRNA-based candidates. Following the discovery of mRNA, which resulted in several scientific breakthroughs, there was a surge in studies in this area, which led to the development of RNA-based vaccines.
North America dominated the next-gen COVID-19 vaccine market in 2024. The dominance of the region is mainly because of the presence of key market players. These market players are highly competitive and continuously collaborate and invest in new research and clinical trials for the development of next-gen COVID-19 vaccines. Apart from this, the region has advanced infrastructure and government support for conducting studies and testing. Countries like the U.S. and Canada are the major contributors to the region’s dominance.
The U.S. has made progress toward a yearly COVID-19 booster program within the last five years. The U.S. strategy has been the most aggressive when compared to vaccination programs in all of Europe. The FDA's new COVID-19 concept strikes a compromise between a dedication to gold-standard research and regulatory flexibility. In addition to approving vaccinations for high-risk individuals, the FDA will need solid, gold-standard data on low-risk individuals. In addition to helping the FDA choose its future course, these clinical studies will yield knowledge that the American public and healthcare professionals sorely need.
Canada boasts one of the highest immunization rates in the world because of a strong vaccine supply plan. For 2023 and beyond, Canada has obtained vaccinations from Pfizer, Moderna, and Novavax, with the possibility to buy extra doses if necessary. Once Health Canada has approved the use of next-generation COVID-19 vaccines, which are created by vaccine providers to guard against mutations or variations of concern, these agreements also give people the freedom to acquire them.
Asia Pacific is estimated to host the fastest-growing next-gen COVID-19 vaccine market during the forecast period. Asia Pacific has a large population base, which increases the chances of COVID-19 cases growth. Governments are taking major steps to develop new vaccines to tackle the growing issue of virus mutation. Companies are collaborating in order to advance in vaccine development.
China is still taking stringent steps to stop the spread of SARS-CoV-2 as of 2025. China has stuck to its "dynamic zero-COVID" strategy, even while the rest of the world has embraced a "living with the virus" mentality. This entails strict traveler quarantine regulations, widespread testing programs, and regional lockdowns. With the extensive dissemination of updated vaccinations that target new variations, China's immunization plan has placed a strong emphasis on local vaccine manufacture. China has adopted next-generation vaccinations by 2025, bringing it closer to international norms.
As more businesses are ready to introduce them in response to an increase in new cases in various regions of the world, namely Singapore, next-generation COVID-19 vaccinations may soon be accessible in India. A next-generation COVID-19 vaccine to fight the XBB1.5 strain of the Sars-CoV-2 virus has started clinical testing, and Hyderabad-based Biological E anticipates early results. With a local clinical trial waiver for emergency use, a Subject Expert Committee (SEC) last month suggested authorizing the Pune-based Serum Institute of India (SII) to develop a Covid-19 vaccine based on the Omicron XBB1.5 version.
Europe is expected to grow significantly in the next-gen COVID-19 vaccine market during the forecast period. Increased research funding and the existence of regionally significant market players are responsible for the industry's expansion. Due to rising investments, Europe is seeing an increase in the number of biopharmaceutical businesses. Furthermore, the market is expanding as a result of the European Medicines Agency's (EMA) simplification of regulatory approvals in order to hasten the launch of novel vaccines. Additionally, the market is expanding as a result of rising expenditures in pandemic preparation, which are supporting the creation of next-generation vaccines for newly developing infectious illnesses. Similarly, market demand is being supported by increased investment for vector-based and mRNA technologies that improve manufacturing efficacy and efficiency.
One of the world's most inventive nations for a long time has been Germany. Another illustration of Germany's diverse scientific and innovative environment is BioNTech. By 2025, Germany is on track to meet its goal of allocating 3.5% of its GDP to research and innovation. The goal of the Medical Research Act, which went into effect in full on October 30, 2024, is to maintain Germany's competitiveness as a pharmaceutical site. It specifically calls for adjustments to expedite approval processes, simplify contract negotiations, and enhance inter-authority collaboration.
Early on in the COVID-19 pandemic, the National Institute for Health and Care Research (NIHR) created a single, UK-wide procedure to rank COVID-19 research as urgent public health research. In a variety of patient cohorts and throughout all stages of human trials, the Department of Health and Social Care (DHSC) is still funding a number of national clinical trial "platforms." With assistance from the NIHR Clinical Research Network around the United Kingdom, they are evaluating a number of therapeutic and preventative possibilities in order to find and enroll patients.
By Region
May 2025
April 2025
May 2025
May 2025